What do systematic reviews say?

Flutamide 250 mg once to b.i.d. vs metformin 1275 mg to 1700 mg per day

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 95 participants
  Moderate

Flutamide 250 mg once to b.i.d. vs metformin 1275 mg to 1700 mg per day

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 95 participants
  Very low

Flutamide 250 mg once to b.i.d. vs metformin 1275 mg to 1700 mg per day

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 55 participants
  Moderate

Finasteride 5 mg vs flutamide 250 mg once to b.i.d.

Finasteride 5 mg showed no clear difference in participant‐reported improvement of hirsutism 4‐point Likert scale compared with flutamide 250 mg once to b.i.d. (low certainty).

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  RR 0.63 [0.31, 1.25]
  1 study · 20 participants
  Low

Finasteride 5 mg vs flutamide 250 mg once to b.i.d.

The review found no eligible studies for this question.

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Finasteride 5 mg vs flutamide 250 mg once to b.i.d.

It is very uncertain whether finasteride 5 mg changes proportion of participants who reported an adverse event compared with flutamide 250 mg once to b.i.d. (very low certainty).

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  RR 3.87 [0.57, 26.24]
  3 studies · 115 participants
  Very low

Ethinyl estradiol 35 μg + cyproterone acetate 2 mg vs ethinyl estradiol 30 μg + desogestrel 0.15 mg

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 136 participants
  Moderate

Finasteride 5 mg vs flutamide 250 mg once to b.i.d.

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 226 participants
  Very low

Finasteride 5 mg vs flutamide 250 mg once to b.i.d.

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 226 participants
  Moderate

Finasteride 5 mg vs flutamide 250 mg once to b.i.d.

The review found no eligible studies for this question.

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Finasteride 5 mg vs flutamide 250 mg once to b.i.d.

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 110 participants
  High

Ethinyl estradiol 35 μg + cyproterone acetate 2 mg vs ethinyl estradiol 30 μg + desogestrel 0.15 mg

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 100 participants
  Moderate

Flutamide 250 mg b.i.d. vs placebo

Flutamide 250 mg b.i.d. may leads to higher participant‐reported improvement of hirsutism 4‐point Likert scale compared with placebo (low certainty).

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  RR 17 [1.11, 259.87]
  1 study · 20 participants
  Low

Flutamide 250 mg b.i.d. vs placebo

The review found no eligible studies for this question.

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

FAE vs placebo

• Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 418 participants
  Low

FAE vs MTX

• Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

FAE vs MTX

It is very uncertain whether FAE changes common nuisance AEs (not leading to treatment discontinuation) compared with MTX (very low certainty).

• Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
  RR 0.89 [0.77, 1.03]
  1 study · 54 participants
  Very low

FAE vs MTX

It is very uncertain whether FAE changes PASI 50 compared with MTX (very low certainty).

• Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
  RR 0.71 [0.41, 1.22]
  1 study · 51 participants
  Very low

FAE vs MTX

It is very uncertain whether FAE changes PASI 75 compared with MTX (very low certainty).

• Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
  RR 0.8 [0.28, 2.29]
  1 study · 51 participants
  Very low

FAE vs MTX

It is very uncertain whether FAE changes PASI 90 compared with MTX (very low certainty).

• Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
  RR 0.48 [0.05, 4.98]
  1 study · 51 participants
  Very low